

WuXi AT expands service capabilities

14 January 2020 | News

Launches New World-Class AAV Vector Suspension Platform



US based WuXi Advanced Therapies (AT), a leading global Contract Development and Manufacturing Organization (CDMO) offering end-to-end contract services for the advance therapies industry, has announced the expansion of its service capabilities by offering a fully integrated adeno-associated virus (AAV) Vector Suspension Platform to help accelerate the timeline for cell and gene therapy development, manufacturing and release while providing greater predictability.

This service will provide advanced therapy companies worldwide with an integrated platform for AAV vector production that includes: in-stock raw materials with established batch records; regulatory and technical expertise; process and analytical development; full in-process and release testing; robust quality control and quality assurance oversight; and facilities that offer the capacity and flexibility to meet client timeline needs with enhanced scalability that range up to 1000L.

"We are excited to bring a world-class AAV Suspension Platform to our customers," said Felix Hsu, Senior Vice President and Global Head of WuXi AppTec Advanced Therapies. "We will continue to develop platforms that help our customers bring their innovative therapies to patients and to market with even greater predictability and speed."